Cramer sees 'breakout' for this stock By: CNBC.com News September 02, 2014 at 10:29 AM EDT That clinical trials for a cholesterol-lowering drug exceed expectations will boost the developer's stock, says CNBC's Jim Cramer. Read More >> Related Stocks: Credit Suisse Group Credit Suisse Group ADR Regeneron Pharmaceuticals Sanofi-Aventis S.A. ADR